Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Business,People,,Double,Exposure,And,Handshake,Closeup,For,Agreement,,City

MannKind Corporation (NASDAQ:MNKD) on Monday agreed to acquire scPharmaceuticals Inc. (NASDAQ:SCPH) for a deal value of up to approximately $360 million, or $5.35 per share.

The deal marks MannKind’s strategic expansion into cardiorenal medicine, establishing its cardiometabolic business alongside its orphan lung division. It is also made possible on the heels of MannKind’s $500 million strategic financing agreement with Blackstone.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.